EU grants marketing authorization for teriflunomide for MS
Posted: Mon Sep 02, 2013 12:39 am
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide).
Genzyme, announced that the European Commission has granted marketing authorization for Aubagio®(teriflunomide) 14 mg, a once-daily, oral therapy indicated for the treatment of adult MSers with relapsing remitting multiple sclerosis (RRMS)....... Read More - http://www.ms-uk.org/index.cfm/aubagio
Genzyme, announced that the European Commission has granted marketing authorization for Aubagio®(teriflunomide) 14 mg, a once-daily, oral therapy indicated for the treatment of adult MSers with relapsing remitting multiple sclerosis (RRMS)....... Read More - http://www.ms-uk.org/index.cfm/aubagio